CFOs Feel Healthcare Pain Rising as GLP-1s Stretch Budgets: Mercer

Why It Matters

Rising health‑benefit costs threaten corporate profitability and could force firms to alter compensation, hiring, or pricing strategies, reshaping the broader labor market and consumer pricing dynamics.

Key Takeaways

• 75% of CFOs list healthcare among top five expense concerns
• Employer health costs projected to rise 6.7% in 2026, exceeding $18,500 per employee
• GLP‑1 drugs cost $1,000‑$1,500 monthly; employers cover up to 100%
• Only 25% of CFOs can absorb rising costs without operational impact
• Half of firms with 500+ employees cover GLP‑1s; coverage may slow

Pulse Analysis

The latest Mercer National Survey underscores a seismic shift in corporate budgeting: health‑benefit inflation is outpacing all other cost categories. While overall inflation has eased, the surge in GLP‑1 medications—priced between $1,000 and $1,500 a month and often fully reimbursed—has driven Medicare spending to roughly $27.5 billion in 2024, a five‑fold increase from 2019. CFOs are now flagging healthcare as a top‑three concern, up from 19% in 2024, reflecting the volatility that self‑funded plans must navigate.

Projected employer health‑insurance costs will rise 6.7% in 2026, the steepest jump in 15 years, lifting the average per‑employee expense to more than $18,500. Even after planned cost‑saving measures, this figure eclipses the prior anticipated 9% increase, indicating that budgetary pressures are deepening. In response, nearly half of surveyed finance leaders favor redesigning plans—higher deductibles, altered cost‑sharing, or stricter eligibility—while fewer support shifting premium burdens onto employees. These adjustments aim to temper claim volatility without eroding the value of benefits.

The operational ripple effects are already visible. Only about 25% of CFOs report being able to absorb health‑cost growth without compromising wage hikes, hiring plans, or product pricing. Companies are therefore exploring utilization‑management tactics for GLP‑1s, such as eligibility controls and mandatory participation in support programs, to ensure therapeutic efficacy while curbing spend. As coverage for these drugs plateaus, firms that master cost‑containment while preserving employee health outcomes will gain a competitive edge in talent attraction and retention.